Hepatology

Papers
(The H4-Index of Hepatology is 69. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies2770
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis2366
Honey, I shrunk the tumor: Downstaging HCC before liver transplantation2122
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction1569
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis547
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury351
Reply: Medications promoting abstinence in alcohol-associated cirrhosis342
Late-Breaking Abstracts295
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks261
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol244
Cover Image208
Letter to the editor: The precise relationship between MELD and survival without a liver transplant203
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive201
Letter to the Editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis190
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy178
Reply154
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?149
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST146
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8143
Reply: Timing shapes adjuvant PD-1 efficacy after hepatectomy in HCC143
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis140
Reply: The PNPLA3 paradox—Does genotype modify the clinical utility of the MASLD framework in children?133
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice131
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease124
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals124
Definition, diagnosis, and treatment of primary biliary cholangitis - autoimmune hepatitis (PBC-AIH) variant: An international expert delphi consensus123
Regulatory role and translational potential of CCL11 in liver fibrosis121
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients119
Plasma proteomic signature of fatty liver disease: The Rotterdam Study117
Efficacy and safety of infliximab in patients with autoimmune hepatitis115
Development and validation of risk stratification models for hepatocellular cancer: A framework from the translational liver cancer consortium114
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates110
Access to technology to support telehealth in areas without specialty care for liver disease107
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution106
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis106
Low-dose chemotherapy remodels hepatic immune landscape and potentiates antitumor response to immune checkpoint blockade in cholangiocarcinoma103
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma102
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death101
Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD101
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study101
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC99
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis97
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor97
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease96
95
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma92
Genes that fit just right: Unzipping the genome of fatty liver disease91
In vivo imaging of calcium dynamics in zebrafish hepatocytes90
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?90
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease88
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?86
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis85
Reply82
Retraction: Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma81
Reply: The CRAPT-M score: Robust enough for clinical practice?81
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma80
The digital determinants of liver disease79
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men79
Amplification of genetic and metabolic factors in alpha-1 antitrypsin deficiency78
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis78
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism77
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study76
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis75
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats75
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?75
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation75
Letter to the Editor: Overlooking the important factor: Hypoxia74
Emergence of highly profibrotic and proinflammatory Lrat + Fbln2 + HSC subpopulation in alcoholic hepatitis73
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known73
Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness69
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response69
0.099071979522705